- Home
- CBL vs TRVI Comparison
CBL vs TRVI Comparison
Compare CBL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBL
- TRVI
- Stock Information
- Founded
- CBL 1978
- TRVI 2011
- Country
- CBL United States
- TRVI United States
- Employees
- CBL N/A
- TRVI N/A
- Industry
- CBL Real Estate Investment Trusts
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- CBL Real Estate
- TRVI Health Care
- Exchange
- CBL Nasdaq
- TRVI Nasdaq
- Market Cap
- CBL 777.7M
- TRVI 725.7M
- IPO Year
- CBL 1993
- TRVI 2019
- Fundamental
- Price
- CBL $27.37
- TRVI $7.87
- Analyst Decision
- CBL
- TRVI Strong Buy
- Analyst Count
- CBL 0
- TRVI 9
- Target Price
- CBL N/A
- TRVI $19.94
- AVG Volume (30 Days)
- CBL 149.8K
- TRVI 1.9M
- Earning Date
- CBL 08-08-2025
- TRVI 08-07-2025
- Dividend Yield
- CBL 5.85%
- TRVI N/A
- EPS Growth
- CBL 2069.88
- TRVI N/A
- EPS
- CBL 2.16
- TRVI N/A
- Revenue
- CBL $528,212,000.00
- TRVI N/A
- Revenue This Year
- CBL N/A
- TRVI N/A
- Revenue Next Year
- CBL N/A
- TRVI N/A
- P/E Ratio
- CBL $12.66
- TRVI N/A
- Revenue Growth
- CBL 0.03
- TRVI N/A
- 52 Week Low
- CBL $21.10
- TRVI $2.36
- 52 Week High
- CBL $33.54
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- CBL 62.61
- TRVI 74.32
- Support Level
- CBL $26.00
- TRVI $6.67
- Resistance Level
- CBL $27.86
- TRVI $8.11
- Average True Range (ATR)
- CBL 0.53
- TRVI 0.41
- MACD
- CBL 0.11
- TRVI 0.17
- Stochastic Oscillator
- CBL 78.95
- TRVI 89.66
About CBL CBL & Associates Properties Inc.
CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.